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Danshensu (3-(3, 4-dihydroxyphenyl) lactic acid), a water-soluble active component isolated from the root of Salvia miltiorrhiza
Bunge, is widely used for the treatment of cerebrovascular diseases. The present study aims to investigate the role of P-
glycoprotein in transport of Danshensu across the blood-brain barrier. Sprague-Dawley rats were pretreated with verapamil at a
dose of 20mgkg−1 (verapamil group) or the same volume of normal saline (control group). Ninety minutes later, the animals
were administrated with Danshensu (15mg kg−1) by intravenous injection. At 15 min, 30min, and 60min after Danshensu
administration, the levels of Danshensu in the blood and brain were detected by high-performance liquid chromatography-
electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). The results showed that Danshensu concentrations in the
brainoftheratspretreated withverapamilwere signiﬁcantlyincreased.Inaddition,thebrain-plasmaratiosofthegrouppretreated
withverapamilweremuchhigherthanthatofthecontrolgroup.There wasnodiﬀerence inDanshensulevelinplasmabetween the
verapamil group and control group. The ﬁndings indicated that Danshensu can pass the blood-brain barrier, and P-glycoprotein
plays an important role in Danshensu transportation in brain.
1.Introduction
The blood-brain barrier (BBB) is a diﬀusion barrier, con-
sisting of an interdependent network of cells designed
to segregate the central nervous system (CNS) from the
systemic circulation. BBB can prevent the movement of
drugs from the blood into the brain, and therefore acts as
an obstacle for the systemic delivery of neurotherapeutics.
Furthermore, eﬄux transport systems may target the drugs
and export them from the brain, in which P-glycoprotein (P-
gp) plays a crucial role.
P-gp is a member of the ATP-binding cassette superfam-
ilyof transmembrane transporters which mediates the mem-
branetransport ofmany hydrophobiccompounds,including
hormones, sterols,lipids, phospholipids,cytokines,and anti-
cancer drugs [1]. P-gp is located in many tissues and in the
capillary endothelial cells of the testis and the BBB, where it
functions asaneﬄuxtransporter ofxenobiotics.Interactions
with substances that inhibit P-gp are of great interest, as
they can potentially enhance the absorption of important
medicines that are generally poorly absorbed, such as drugs
for CNS. Verapamil is the most extensively characterized
P-gp inhibitor and multidrug resistance-associated protein
(MDR) reversal agent [2]. It is also reported that coad-
ministration of verapamil with a recognized antidepressant
(imipramine) improves the clinical outcome in previously
resistant cases and the inhibition of P-gp was a potential
mechanism of action for verapamil during treatment resis-
tant depression [3].
Danshen, the dried root of Salvia miltiorrhiza Bunge, is
widely used for the treatment of various microcirculatory
disturbance-related diseases, such as cardiovascular disease,
liver dysfunction, and cerebrovascular disease [4]. Chemical
constituents of Salvia miltiorrhiza Bunge are classiﬁed into
two major categories: lipophilic compounds (such as Tan-
shinone) and hydrophilic compounds (such as Danshensu).
Studies have showed that lipophilic compounds Tanshi-
none I, Tanshinone IIA, Cryptotanshinone, and 15, 16-
dihydrotanshinone I had the ability to ameliorate memory
deﬁcits induced by scopolamine [5]; Tanshinone IIA and2 Evidence-Based Complementary and Alternative Medicine
Tanshinone IIB could lead to reduction of brain infarct
volume and the restoration of neurological function in an
experimental model of stroke in mice [6]; Cryptotanshinone
could improve the cognitive ability in Alzheimer’s disease
transgenic mice [7]. Besides, Tanshinone I [8], Tanshinone
IIA [9], and Cryptotanshinone [10] were also found to be
the substrates of P-gp. However, it is still unclear whether
Danshensu, a hydrophilic compound in Danshen, has the
potential of crossing the BBB or is the substrate of P-gp.
The present study aims to investigate the role of P-gp in
the transport of Danshensu across the BBB by observing
Danshensu concentration in plasma and brain tissue in
rats.
2.MaterialandMethods
2.1. Drugs and Chemicals. Danshensu (Purity 99.6%) was
obtained from Shandong Luye Pharmaceutical Co., Ltd.
(Yantai, China). Verapamil was obtained from Shang-
hai Hefeng Pharmaceutical Co., Ltd. (Shanghai, China).
Naproxen (Purity 99.9%) was obtained from National
Institute for the Control of Pharmaceutical and Biological
Products. Ethyl acetate (analytical reagent) was obtained
from Sinopharm Chemical Reagent Co., Ltd. (Shanghai,
China). Acetonitrile (Purity 99.9%) was obtained from
Merck (Darmstadt, Germany).
2.2. Animals and Treatment. Forty-eight male Sprague Daw-
ley rats weighing 220 ± 20g were provided by the Exper-
imental Animal Center of Shandong Engineering Research
Centerfor Natural Drugs (Yantai, China), certiﬁcate number
20030020. All experimental procedures carried out in this
study were performed in accordance with the guidelines
for the Care and Use of Laboratory Animals of Yantai
University. The rats were kept with free access to food
and water on a 12h light/dark cycle. They were housed
in plastic cages and randomly divided into two groups
with 24 animals in each group: the control group and the
verapamil group. The rats in the verapamil group were
administered intraperitoneally with verapamil at a dose of
20mgkg−1. The rats in the control group were treated
with the same volume of normal saline. Ninety minutes
later, all rats were treated intravenously with Danshensu
(15mgkg−1, i.v.) by tail vein. At 15min, 30min, and 60min
after Danshensu treatment, the animals were anesthetized
with chloral hydrate (300mgkg−1, i.p.) and then 5mL
heparinized blood (1% heparin, 100μL) were collected
from abdominal aorta and the rats were perfused with
100mL of ice-cold normal saline each. The brain was
rapidly removed from the cranium and weighed. Then the
brain was homogenized in 4 volumes of 0.1molL−1 ice
phosphate buﬀer (pH 7.4). Three milliliters of ethyl acetate
was added into 200μL of the homogenate. After vortexing
for 3min and centrifuging (2500g, 4◦C) for 5min, the
supernatants were evaporated to dryness under a gentle
nitrogen stream at 40◦C. The residues were resuspended
in mobile phase (the composition will be referred in
the following text). The blood samples were centrifugated
(2500g, 4◦C) for 10min and plasma was separated. Plasma
was treated as described for brain homogenate super-
natants.
2.3.Chromatographic Conditions. The chromatographicsep-
aration was performed using an Agilent 1100 Series HPLC
system equipped with a vacuum degasser, a quaternary
pump, an autosampler, and a column oven. The chromato-
graphic separation was run on a Hanbon ODS-C18 column
(150 × 2.1mm, 3μm). The mobile phase was acetonitrile-
water (55:45, v/v). The pump was operated at a ﬂow
rate of 0.2mLmin−1. Separations were performed at the
temperature of 20◦C.
2.4. Mass Spectrum Conditions. Mass spectrometric detec-
tion was performed using a TSQ Quantum tandem mass
spectrometer equipped with an electrospray ionization (ESI)
source (Thermo Electron Corporation, USA). Quantiﬁca-
tion was performed using selected reaction monitoring
(SRM) of the transitions of m/z 197.0 → m/z 135.1 for
Danshensu and m/z 229.0 → m/z 170.1 for the naproxen
(Internal Standard). The mass spectrum conditions were
optimized as follows: spray voltage, 3000V; sheath gas pres-
sure, 30psi; auxiliary gas pressure, 5 arbitrary unit; capillary
temperature, 350◦C; collision-induced dissociation voltage,
18V; argon gas pressure, 1.5 millitorr. Data acquisition was
performed with Xcalibur software.
Ionization was operated in negative Selected Ion Moni-
toring (SIM) mode. Sheath gas (N2) pressure was 30kPa and
aux gas (N2) pressure was 5kPa. Capillary temperature was
150◦C. Ion sweep gas pressure was 0kPa and Tube Lens oﬀset
was 105eV.
2.5. Statistical Analysis. Data is expressed as means ± SEM.
The statistical signiﬁcances of the data were determined
using one-way analysis ofvariance (ANOVA)followed by the
Least Signiﬁcant Diﬀerence testing. The P value <. 05 was
considered as statistically signiﬁcant.
3.Results
3.1. High-Performance Liquid Chromatogram of Danshensu.
Figures 1 and 2 show the typical SRM chromatograms of the
blankratbrain;brain spikedwith Danshensu (Standard)and
naproxen(InternalStandard);brainofDanshensutreatedrat
withspikeofnaproxen(InternalStandard);blankratplasma;
plasma spiked with Danshensu and naproxen; plasma of
Danshensu treated rat with spike of naproxen. The retention
times of Danshensu and naproxen were 1.8 and 4.2min in
brain and 1.7 and 4.3min in plasma, respectively.
3.2.EﬀectofVerapamil onDanshensu Concentrations inBrain.
At 15min, 30min, and 60min after Danshensu treatment,
Danshensu concentrations in the brain of the verapamil
groupweresigniﬁcantlyhigherthanthatofthecontrolgroup
(1.67, 3.32 and 2.80 fold, resp., P<. 01, Figure 3).Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: SRM chromatograms of Danshensu and naproxen
(InternalStandard)inblankratbrain(a),blankbrainsamplespiked
with Danshensu (Standard) and naproxen (b) and Danshensu
treated rat brain spike with naproxen (c).
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Figure 2: SRM chromatograms of Danshensu and naproxen in
blank rat plasma (a), blank plasma sample spiked with Danshensu
and naproxen (b) and Danshensu treated rat plasma spike with
naproxen (c).
3.3. Eﬀect of Verapamil on Danshensu Concentrations in
Plasma. Compared with control, pretreatment with vera-
pamil had no eﬀect on Danshensu concentrations in plasma
(Figure 4).
3.4. Eﬀect of Verapamil on Danshensu Concentrations in
Brain:Plasma Ratios. At 15min, 30min, and 60min after
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Figure 3: Eﬀect of verapamil on Danshensu concentration in
rat brain. Data was expressed as mean ± SEM (n = 8).
Statistical signiﬁcances were determined using one-way analysis
of variance (ANOVA) followed by the Least Signiﬁcant Diﬀerence
testing. ∗∗P<. 01 compared with control group.
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Figure 4: Eﬀect of verapamil on Danshensu concentration in rat
plasma. Data was expressed as mean ± SEM (n = 8). Statistical
signiﬁcances were determined using one-way analysis of variance
(ANOVA) followed by the Least SigniﬁcantDiﬀerence testing.
Danshensu treatment, the brain-plasma ratios in Dan-
shensu concentrations of verapamil group were signiﬁcantly
increased (P<. 01, Figure 5).
4.Discussion
BBB, being made up of the brain capillary endothelial cells
which are connected to each other by well-developed tight
junctions, is a lipoid membrane barrier. Because of its
strict regulation on the movement of compounds from the
circulating blood into the brain, permeation of xenobiotics
across the BBB has long been believed to be dependent on
their lipophilicity. However, increasing studies reported that4 Evidence-Based Complementary and Alternative Medicine
the permeation of the highly lipophilic drugs, for example,
vinca alkaloid, doxorubicin, and cyclosporin A, across the
BBB is unexpectedly low. Studies on the BBB transport of
xenobiotics, as well as nutrients and neuroactive agents,
have led to a change in the concept of the BBB. BBB is
no longer regarded as a static lipoid membrane barrier of
endothelial cells, but rather is considered to be a dynamic
interface that has physiological functions for the speciﬁc
and selective transmembrane transport of many compounds
[11].
The apparently contradictory observations can be as-
cribed to the existence of multiple mechanisms of drug
transport through the BBB. The MDR1 gene product P-gp is
a membrane protein, which functions as an ATP-dependent
exporter of xenobiotics from cells. P-gp is expressed in
normal tissues with excretory functions such as the intestine,
liver, kidneys, and capillary endothelial cells of the brain.
Several studies pointed to a predominant role of the eﬄux
transporter P-gp as a major gatekeeper in the BBB [12,
13]. P-gp has a profound eﬀect on the entry of drugs,
peptides and other substances into the CNS. High level
of expression, multispeciﬁcity, and high transport potency
m a k e sP - g pa sap r i m a r yo b s t a c l et od r u gd e l i v e r yi n t o
the brain, thereby contributing to the poor success rate
of a large range of therapeutic candidates, and probably
contributing to patient-to-patient variability in response
to CNS pharmacotherapy. Although it reported that Dan-
shensu had a protective eﬀect against experimental impair-
ment of memory induced by cerebral ischemia reperfusion
[14], it remains unclear whether Danshensu could cross
BBB.
Our resultsdemonstrated that at 15min after Danshensu
administration, its concentration in the brain reached a
relatively high level in both the control and verapamil
groups, which indicates that Danshensu can cross the
BBB. Furthermore, the concentration of Danshensu in the
verapamil group was much higher than that of control, but
verapamil did not aﬀect the concentration of Danshensu in
plasma, which suggested that the eﬀect of verapamil on the
concentration of Danshensu in the brain did not depend on
the interfering of the elimination of Danshensu from blood.
Inturn,itmaybededucedthatP-gpplayedanimportantrole
in eﬄuxion of Danshensu from the brain because verapamil,
as an inhibitor of P-gp, could increase the concentration of
Danshensu in the brain.
It should be noted that the present experiment only
evaluated the role of P-gp which played on Danshensu.
However, the eﬀect of Danshensu on P-gp expression has
not been taken into consideration. As a result, our further
studieswill focuson whether Danshensu couldmodulate the
function or expression of P-gp.
In summary, the present study demonstrated that Dan-
shensu can pass BBB. It was also indicated that inhibiting P-
gp could therefore increase the concentration of Danshensu
in brain. Subsequently, our studies highlight the importance
of P-gp inhibitor as a coadministration with Danshensu in
the therapy of CNS disorders.
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Figure 5: Eﬀect of verapamil on brain:plasma ratio of Danshensu
concentration in rats. Data was expressed as mean ± SEM (n =
8). Statistical signiﬁcances were determined using one-way analysis
of variance (ANOVA) followed by the Least Signiﬁcant Diﬀerence
testing. ∗∗P<. 01 compared with control group.
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